Asunto(s)
Anticoagulantes/uso terapéutico , Síndrome Antifosfolípido/diagnóstico , Síndrome de Budd-Chiari/diagnóstico , Lupus Eritematoso Sistémico/complicaciones , Plasmaféresis , Dolor Abdominal/sangre , Dolor Abdominal/etiología , Dolor Abdominal/terapia , Adolescente , Anticuerpos Anticardiolipina/sangre , Anticuerpos Anticardiolipina/inmunología , Anticuerpos Antinucleares/sangre , Anticuerpos Antinucleares/inmunología , Síndrome Antifosfolípido/sangre , Síndrome Antifosfolípido/inmunología , Síndrome Antifosfolípido/terapia , Ascitis/sangre , Ascitis/etiología , Ascitis/terapia , Síndrome de Budd-Chiari/sangre , Síndrome de Budd-Chiari/inmunología , Síndrome de Budd-Chiari/terapia , Femenino , Venas Hepáticas/diagnóstico por imagen , Humanos , Lupus Eritematoso Sistémico/sangre , Lupus Eritematoso Sistémico/inmunología , Náusea/sangre , Náusea/etiología , Náusea/terapia , Tomografía Computarizada por Rayos X , Ultrasonografía , Vómitos/sangre , Vómitos/etiología , Vómitos/terapiaRESUMEN
An esophageal stricture is one of the complications that may develop during cancer treatment in children. Although more commonly associated with radiotherapy, recurrent mucositis has also been implicated. Presented herein is a case of a patient with acute lymphoblastic leukemia who suffered recurrent attacks of severe mucositis. Initial management of ensuing dysphagia included antifungal treatment for candida esophagitis. A subsequent upper endoscopy due to persistence of dysphagia revealed the presence of an esophageal stricture. Our aim in presenting this case is to emphasize the importance of considering a diagnosis of esophageal stricture in patients receiving anti-cancer treatment; early endoscopic intervention may be warranted in some patients.
Asunto(s)
Estenosis Esofágica/etiología , Mucositis/complicaciones , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicaciones , Niño , Dilatación/métodos , Estenosis Esofágica/terapia , Humanos , Masculino , RecurrenciaRESUMEN
To apply and determine whether standardized mortality scores are appropriate to predict the risk of mortality in mechanically ventilated pediatric patients, 150 patients were retrospectively evaluated. Pediatric risk of mortality (PRISM) III-24 and pediatric index of mortality (PIM)-2 scores were unable to discriminate survivors and nonsurvivors; the observed mortality rate was lower than expected mortality rates. Oxygenation index (OI) was calculated at 0, 12, 24, and 72 hours of ventilation. OI-12 and OI-72 were found to be higher in nonsurvivors. PRISM III-24 and PIM-2 scores failed to predict mortality risk in mechanically ventilated pediatric patients. OI can be used to predict degree of respiratory failure and mortality risk.